Ketones and diabetes drug for heart failure with weak pump
Treatments studied
Part of Hormones & metabolism clinical trials.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have type 2 diabetes.
- You have heart failure with a reduced pumping ability (ejection fraction below 50%) and mild to moderate symptoms.
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 23 and 44.
- Your blood sugar control (A1c) is between 6.0 and 10.0%.
- You have not gained or lost more than 4 pounds in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests whether taking a special oral ketone supplement can help people with both heart failure and diabetes. It looks at both short-term and long-term effects on heart function and blood sugar control.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
Hear when a new Type2diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.